A$33.55 0.0 0.0%
Last Trade - 13/09/18
| Market Cap | ÂŁn/a |
| Enterprise Value | ÂŁn/a |
| Revenue | ÂŁ124.0m |
| Position in Universe | th / 1832 |
| Industry | Market | |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
| Year End 30th Jun | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019E | 2020E | CAGR / Avg | |
|---|---|---|---|---|---|---|---|---|---|---|
| 99.2 | 131.2 | 178 | 234.7 | 236.9 | 220.7 | 247.2 | 256.6 | +17.3% | ||
| +5.8 | +29.3 | +68.7 | +32.2 | -37.9 | +27.7 | +49.9 | +7.66 | |||
|
x
|
||||||||||
| Profitability | ||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
| Cashflow | ||||||||||
| Dividends | ||||||||||
| Balance Sheet | ||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing % | |||
| Net Gearing % | |||
| Cash / Assets % |
| Liquidity (ttm) | ||
|---|---|---|
| Curr. Ratio | ||
| Quick Ratio | ||
| Interest Cov. | ||
| Efficiency (ttm) | ||
|---|---|---|
| Asset Turnover | ||
| Recs Turnover | ||
| Stock Turnover | ||
| Latest interim period vs. prior period | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
| 3yr Compound Annual Growth Rate | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
Revenue
Net Income
Normalised EPS
PE Ratio Range
Dividend Yield Range
|
Price Target:
( below Price)
|
31st Dec 2021
|
31st Dec 2022
|
||||
|---|---|---|---|---|---|---|
| Est. Long Term Growth Rate: |
Net Profit () |
EPS () |
DPS () |
Net Profit () |
EPS () |
DPS () |
| Consensus Estimate | ||||||
| 1m Change | ||||||
| 3m Change | ||||||
Sirtex Medical Limited is a medical device company with primary objective of manufacturing and distributing liver cancer treatments utilizing small particle technology to markets in Asia-Pacific; Europe, the Middle East and Africa (EMEA), and North and South America. The Company's segments include Asia Pacific, Americas and EMEA. Its lead product is SIR-Spheres Y-90 resin microspheres, which is a targeted radioactive treatment for liver cancer. The treatment is called Selective Internal Radiation Therapy (SIRT) and consists of a minimally invasive surgical procedure performed by an interventional radiologist. The SIR-Spheres microspheres lodge in the small blood vessels of the tumor where they destroy it from the inside while sparing the surrounding healthy tissue. The Company is also engaged in conducting other studies, which include SIRFLOX and FOXFIRE Global for liver metastases, and RESIRT for primary renal cell carcinoma. SIR-Spheres is available in over 40 countries.
| Last Annual | June 30th, 2018 |
| Last Interim | June 30th, 2018 |
| Incorporated | April 21, 1997 |
| Public Since | August 24, 2000 |
| No. of Shareholders: | 8,322 |
| No. of Employees: | 292 |
| Sector | Healthcare |
| Industry | Healthcare Equipment & Supplies |
| Index | |
| Exchange | Australian Stock Exchange - SEATS |
| Shares in Issue | 55,773,045 |
| Free Float | (0.0%) |
| Eligible for |
ISAs
SIPPs
|
| Address | Shop 6 207 Pacific Hwy, NORTH SYDNEY, 2065, Australia |
| Web | http://www.sirtex.com/ap/ |
| Phone | +61 2 99648400 |
| Contact | Thomas Duthy (Global Investor Relations Manager) |
| Auditors | Grant Thornton Audit Pty Ltd |
As of 13/09/18, shares in Sirtex Medical are trading at A$33.55, giving the company a market capitalisation of ÂŁn/a. This share price information is delayed by 15 minutes.
Shares in Sirtex Medical are currently trading at A$33.55 and the price has moved by 0.113k% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Sirtex Medical price has moved by 0.107k% over the past year.
Of the analysts with advisory recommendations for Sirtex Medical, there are there are currently 0 "buy" , 3 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Sirtex Medical is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Sirtex Medical is scheduled to issue upcoming financial results on the following dates:
Sirtex Medical does not currently pay a dividend.
Sirtex Medical does not currently pay a dividend.
Sirtex Medical does not currently pay a dividend.
To buy shares in Sirtex Medical you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
Shares in Sirtex Medical are currently trading at A$33.55, giving the company a market capitalisation of ÂŁn/a.
Here are the trading details for Sirtex Medical:
We were not able to load our ranking data for Sirtex Medical
We were not able to load any forecast data for Sirtex Medical.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Sirtex Medical. Over the past six months, the relative strength of its shares against the market has been 9.19%. At the current price of A$33.55, shares in Sirtex Medical are trading at % against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
We were not able to find PE ratio data for Sirtex Medical.
We were unable to find the directors for Sirtex Medical.
Here are the top five shareholders of Sirtex Medical based on the size of their shareholding:
